|
Delayed
Japan Exchange
02:30:00 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 5,753.00 JPY | -2.62% |
|
-0.81% | +18.99% |
| 09-04 | After obesity, pharma seeks its next mega-blockbuster in sleep |  |
| 09-04 | Takeda Pharmaceutical Insider Sold Shares Worth $2,148,372, According to a Recent SEC Filing | MT |
Company Valuation: Takeda Pharmaceutical Company Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,423,454 | 6,762,204 | 6,564,378 | 6,749,675 | 8,948,061 | 9,186,153 | - | - |
| Change | - | 24.68% | -2.93% | 2.82% | 32.57% | 2.66% | - | - |
| Enterprise Value (EV) 1 | 8,919,170 | 10,611,015 | 10,950,330 | 10,725,175 | 5,130,461 | 13,092,670 | 12,888,339 | 12,582,574 |
| Change | - | 18.97% | 3.2% | -2.06% | -52.16% | 155.19% | -1.56% | -2.37% |
| P/E | 23.8x | 21.3x | 45.4x | 64.6x | 46.4x | 45.6x | 29x | 23.6x |
| PBR | 0.95x | 1.06x | 0.9x | 1x | 1.2x | 1.23x | 1.23x | 1.22x |
| PEG | - | 0.5x | -0.8x | -2.5x | 0.6x | 12.94x | 0.5x | 1x |
| Capitalization / Revenue | 1.52x | 1.68x | 1.54x | 1.47x | 1.99x | 1.95x | 1.92x | 1.87x |
| EV / Revenue | 2.5x | 2.63x | 2.57x | 2.34x | 1.14x | 2.79x | 2.7x | 2.56x |
| EV / EBITDA | 8.54x | 9.19x | 11.6x | 9.71x | 4.54x | 9.85x | 9.05x | 8.44x |
| EV / EBIT | 19.4x | 21.6x | 51.1x | 31.3x | 12.6x | 27.9x | 21.4x | 18.1x |
| EV / FCF | 8.92x | 28.7x | 43.4x | 15.5x | 8.14x | 18.6x | 18.4x | 17.1x |
| FCF Yield | 11.2% | 3.49% | 2.31% | 6.43% | 12.3% | 5.39% | 5.44% | 5.83% |
| Dividend per Share 2 | 180 | 180 | 188 | 196 | 200 | 204.3 | 208.4 | 215.8 |
| Rate of return | 5.15% | 4.14% | 4.49% | 4.44% | 3.53% | 3.55% | 3.62% | 3.75% |
| EPS 2 | 147.1 | 204.3 | 92.09 | 68.36 | 122 | 126.3 | 198.6 | 243.4 |
| Distribution rate | 122% | 88.1% | 204% | 287% | 164% | 162% | 105% | 88.6% |
| Net sales 1 | 3,569,006 | 4,027,478 | 4,263,762 | 4,581,600 | 4,505,700 | 4,700,830 | 4,781,479 | 4,905,761 |
| EBITDA 1 | 1,043,995 | 1,154,905 | 942,077 | 1,103,982 | 1,129,888 | 1,329,787 | 1,423,902 | 1,490,869 |
| EBIT 1 | 460,844 | 490,505 | 214,100 | 342,600 | 408,800 | 470,109 | 602,847 | 696,837 |
| Net income 1 | 230,059 | 317,017 | 144,067 | 107,900 | 191,800 | 196,495 | 322,439 | 382,719 |
| Net Debt 1 | 3,495,716 | 3,848,811 | 4,385,952 | 3,975,500 | -3,817,600 | 3,906,517 | 3,702,186 | 3,396,421 |
| Reference price 2 | 3,498.00 | 4,350.00 | 4,184.00 | 4,413.00 | 5,664.00 | 5,753.00 | 5,753.00 | 5,753.00 |
| Nbr of stocks (in thousands) | 1,550,444 | 1,554,530 | 1,568,924 | 1,529,498 | 1,579,813 | 1,596,759 | - | - |
| Announcement Date | 5/11/22 | 5/11/23 | 5/9/24 | 5/8/25 | 5/13/26 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 45.55x | 2.79x | 9.85x | 3.55% | 58.86B | |
| 32.72x | 11.9x | 24.26x | 0.6% | 1,024B | |
| 30.62x | - | - | 1.95% | 663B | |
| 32.73x | 7.6x | 15.8x | 2.67% | 453B | |
| 19.89x | 4.73x | 11.71x | 2.8% | 352B | |
| 22.72x | 5.84x | 14.51x | 2.7% | 304B | |
| 20.87x | 4.29x | 12.24x | 2.06% | 252B | |
| 27.66x | 7.14x | 13.15x | 2.31% | 236B | |
| 13.33x | 4.82x | 10.06x | 3.78% | 206B | |
| -46.14x | 6.65x | 25.95x | 2.18% | 187B | |
| Average | 20.00x | 6.19x | 15.28x | 2.46% | 373.72B | |
| Weighted average by Cap. | 24.39x | 7.89x | 17.65x | 1.98% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 4502 Stock
- Valuation Takeda Pharmaceutical Company Limited
Select your edition
All financial news and data tailored to specific country editions
